HeYuan Bio: First Quarter Report for 2026

SZSIApr 28 00:00 · Announcements

First Quarter Report for 2026

SZSIApr 28 00:00 · Announcements

Heyuan Biotech (688238.SH) reported a net loss of 53.0848 million yuan in the first quarter.

Gelonghui reported on April 27 that Heyuan Bio (688238.SH) released its Q1 2026 financial report, showing that the company achieved operating revenue of 50.5405 million yuan in the first quarter, a year-on-year decrease of 4.37%; net profit attributable to shareholders of -53.0848 million yuan; and non-GAAP net profit attributable to shareholders of -54.0122 million yuan.

Gelonghui FinanceApr 27 17:09

Heyuan Biotech (688238): CDMO Orders and Pipeline Progressing Steadily; Cost Reduction and Efficiency Improvement Show Results

The company’s 2025 performance met our expectations. The company announced its 2025 results: revenue reached RMB 268 million, representing a year-on-year increase of 7.88%; gross profit showed a loss of RMB 39 million; net profit attributable to shareholders recorded a loss of RMB 235 million, with the loss narrowing year-on-year.

CICCApr 21 14:07

Heyuan Biotechnology's losses narrowed in 2025, but the gross margin of its CDMO business has yet to turn positive.

①The CRO business is relatively mature, with a stable gross profit margin, whereas the CDMO business involves high technical difficulty. Its gross profit margin correlates with the execution phase and is further influenced by commercial opportunity considerations, exhibiting inherent volatility. ②The short-term competitive landscape in the cell and gene therapy CRO/CDMO industry remains intense, and recovery from price competition for outsourcing orders will take time.

cls.cnApr 21 09:36

Shanghai Obio Technology: Summary of the Annual Report for 2025

SZSIApr 21 00:00 · Announcements